Estuary Biotherapeutics is a biotechnology company developing genetic medicines for serious kidney diseases.
Estuary Biotherapeutics has raised $93.0M in total funding. The most recent round was Series A. The last funding was announced in October 2026.
Estuary Biotherapeutics's investors include RA Capital Management, 4BIO Capital, Google Ventures, Pivotal bioVenture Partners, Deep Track Capital.
Estuary Biotherapeutics is headquartered in San Francisco, United States.
Estuary Biotherapeutics is a biotechnology company developing genetic medicines for serious kidney diseases.
Estuary Biotherapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Estuary Biotherapeutics — Funding & Investors." VCBacked, October 16, 2026, https://www.vcbacked.co/company/estuary-biotherapeutics. Accessed November 5, 2026.
VCBacked. (2026). Estuary Biotherapeutics — Funding & Investors. Retrieved November 5, 2026, from https://www.vcbacked.co/company/estuary-biotherapeutics
{{cite web |title=Estuary Biotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/estuary-biotherapeutics |website=VCBacked |access-date=November 5, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Estuary Biotherapeutics? Request a listing update